Shaowen Cheng

Shaowen Cheng

Auto-generated profile, based on publicly available information

Shaowen Cheng

Department of Wound Repair, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570100, P.R. China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Journal of Environmental Psychology
Verified
Journal Article
Closed access
YZYuling Zhang
Yuling Zhang
HZHong-Lei Zhang
Hong-Lei Zhang
JZJie Zhang
Jie Zhang
SCShaowen Cheng
Shaowen Cheng

11 July 2023 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
RWRong Wang
Rong Wang
HNHan Na
Han Na
SCShaowen Cheng
Shaowen Cheng
YZYanglin Zheng
Yanglin Zheng
JYJiangling Yao
Jiangling Yao
YGYuntao Gu
Yuntao Gu
Osteoporosis is a common disease characterized by reduced bone mass, microstructural deterioration, fragility and consequent fragility fractures and is particularly prevalent among the elderly population. Although glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have positive effects on bones, their role in the prevention of osteoporotic fractures remains to be elucidated. The present study assigned female Sprague Dawley rats with osteoporotic fractures into variectomized osteoporosis (OVX), OVX + liraglutide (LIRA) (50 µg/kg/day subcutaneous LIRA) and control groups. At 3 and 6 weeks postoperatively, X‑ray, tartrate‑resistant acid phosphatase (TRAP) staining, histological and biomechanical assays and assessment of femoral bone mineral density (BMD) were performed. Compared with the OVX group, GLP‑1 RA treatment improved the formation of calluses and osseous union. TRAP staining showed significantly fewer osteoclasts in the OVX + LIRA group compared with the OVX group. In the osteoporotically fractured rats, LIRA improved bone strength at the femoral diaphysis, stiffness, ultimate load and femoral trabecular BMD Compared with the OVX group. GLP‑1 RA treatment inhibited osteoclast formation and improved trabecular bone architecture and mass in osteoporotic fracture model rats, leading to improved biomechanical strength. GLP‑1 RAs may be used as novel anti‑osteoporotic fracture agents.